Inir 10mg, 18mg, 25mg, 40mg, 60mg Capsule
PDF Leaflet Revision Date: 25 November 2016
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of ADHD in children 6 years and older, adolescents, and adults.
Dosage (summary)
Children <70 kg: 0.5 mg/kg, maintenance 1.2 mg/kg/day; Adults: Initiate at 40 mg, maintenance 80 mg.
Onset of Action / Duration
Onset: 1-2 hours, Duration: Not specified.
Special Populations
- Hepatic impairment
- End-stage renal disease
Pregnancy & Breastfeeding
No adequate studies in pregnancy; unknown if excreted in human milk.
Key Drug Interactions
- MAOIs
- Beta-adrenergic agonists
- CYP2D6 inhibitors
Contraindications
- Hypersensitivity to atomoxetine
- Uncontrolled hypertension
- Narrow angle glaucoma
Common side effects
- Decreased appetite
- Suicidal ideation
- Mood swings
- Dizziness
- Palpitations
Counselling Points
- Monitor for mood changes
- Use caution when driving
- Do not open capsules
- Report jaundice or liver symptoms
Serious warnings
- Risk of suicidal behavior
- Liver injury
- Mood swings
- Cardiovascular effects
Important Disclaimer
The Inir 10mg, 18mg, 25mg, 40mg, 60mg Capsule professional information leaflet below is the property of Dr Reddy’S Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
